RxIon Critical Analysis

Brutal Market Reality Reports

Framework v2.0: Assume Failure Until Proven Otherwise

Tirzepatide (Mounjaro/Zepbound)

2/10 Viability Score

Why You'll Fail:

• $10,000+ CAC with $85 CPCs
• Zero supply chain access
• Negative margins on every sale
• Dominated by Ro ($876M funding)

Reality Check:

Selling $950 drug for $299 with $10K acquisition cost

View Full Report →

Naltrexone

3/10 Viability Score

Why You'll Fail:

• $5,000+ CAC with 0.5% conversion
• Generic available for $27 at CVS
• Monument has $27M funding
• Negative unit economics

Reality Check:

Competing against CVS to sell $27 drug for $89

View Full Report →

TRT (Testosterone)

4/10 Viability Score

Why You'll Fail:

• DEA audit = instant death
• 15% get polycythemia = lawsuits
• PeterMD at $99 losing money
• FDA crackdown June 2025

Reality Check:

DEA Schedule III nightmare with stroke liability

View Full Report →